ReviewRheumatology (Oxford, England)2020
Lupus nephritis: clinical presentations and outcomes in the 21st century.
Review in Rheumatology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06654024 (Assessment of Urinary Congophilia as an Indicator of Disease Activity of Lupus Nephritis), which is not on this map. Cited by 134 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Urinary Congophilia as an Indicator of Disease Activity of Lupus Nephritis
Who cites it
134 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Safety and Efficacy of Obinutuzumab in Treating Lupus Nephritis: A Systematic Review.Immunity, inflammation and disease · 2026Pooled it
- Efficacy and safety of belimumab therapy for patients with lupus nephritis: A meta-analysis and a propensity score-matched case-control study.Immunity, inflammation and disease · 2023Pooled it
- Meta-analyses identify DNA methylation associated with kidney function and damage.Nature communications · 2021Pooled it
- Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026Trial
- B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab.International journal of molecular sciences · 2022Trial
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityTrial
- Metabolic determinants of autoimmune kidney diseases.Nature reviews. Nephrology · 2026Review
- Free mycophenolic acid exposure for therapeutic drug monitoring in paediatric lupus nephritis: associations with treatment response and haematologic toxicity.Lupus science & medicine · 2026Article
- Factors associated with clinically significant nephritis in systemic lupus erythematosus patients who present with glomerular hematuria: a cross-sectional study.Rheumatology international · 2026Article
- Clinical outcomes and prognostic factors in lupus nephritis: impact of remission on renal and overall survival in a single-center study.BMC nephrology · 2026Article
- Repeat Kidney Biopsy in Lupus Nephritis: Diagnostic Yield and Clinical Utility in a Real-World Single-Centre Cohort.Journal of clinical medicine · 2026Article
- Screening of diagnostic biomarkers for taurine metabolism-related genes in lupus nephritis and analysis of immune infiltration.International urology and nephrology · 2026Article
- Article
- Inflammation-Driven Lymphoid Structures: Organization, Function, and Clinical Impact Across Autoimmunity, Cancer, and Checkpoint Toxicity.Immunological reviews · 2026Review
- The current state of systemic lupus erythematosus care in the Philippines: a narrative review.Journal of rheumatic diseases · 2026Review
- Serum and urinary soluble CD163 in children with active lupus nephritis.Pediatric rheumatology online journal · 2026Article
- Clinical and Biochemical Factors Associated with Delayed Renal Response in Proliferative Lupus Nephritis: A 20-Year Single-Center Multiethnic Cohort Study.Biomedicines · 2026Article
- Reprogramming M2b Macrophages via GPX1 Activation by Selenium Nanoparticles Attenuates Lupus Nephritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Distinct Longitudinal Trajectories of SLEDAI-2K Scores Predict Prognosis in Systemic Lupus Erythematosus Based on Group-Based Trajectory Modeling.Journal of immunology research · 2026Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lupus nephritis (LN) is a frequent and severe manifestation of SLE. Along the decades, the epidemiology of LN and its clinical presentation have been changing. However, even though retrospective cohort studies report a decreased mortality rate and an improvement in the disease prognosis, the percentage of patients progressing into end stage renal disease (ESRD) keeps steady despite the improvements in therapeutic strategies. Current in-use medications have been available for decades now, yet over the years, regimens for optimizing their efficacy and minimizing toxicity have been developed. Therapeutic research is now moving towards the direction of precision medicine and several new drugs, targeting selectively different pathogenetic pathways, are currently under evaluation with promising results. In this review, we address the main changes and persistent unmet needs in LN management throughout the past decades, with a focus on prognosis and upcoming treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.